Please select the option that best describes you:
Topics:
Cardiology • Cardio-Oncology
Would you recommend that hematologists test for clonal hematopoiesis of indeterminate potential (CHIP) in patients with an intermediate 10-year risk of ASCVD?
Is the data compelling enough to merit intensifying or initiating primary prevention if the patient has CHIP?
Answer from: at Academic Institution
Clonal hematopoiesis of indeterminate potential (CHIP) is a condition where blood cells acquire genetic mutations that give them a growth advantage without causing hematologic abnormalities sufficient to be classified as a blood cancer. It's more common with age and has been associated with an incre...
Sign in or Register to read more